STRO

Sutro Biopharma, Inc. (STRO) - 10-K Summary

Business Context and Reporting Period

Company: Sutro Biopharma, Inc.
Filing Type: Annual Report on Form 10-K
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Sutro is a clinical-stage oncology company developing site-specific antibody-drug conjugates (ADCs) using its proprietary XpressCF and XpressCF+ cell-free protein synthesis platforms. The company has no approved products and generates revenue primarily through collaboration agreements.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: The company reported a non-cash interest expense of $38.2 million related to the sale of future royalties to Blackstone.

Material Changes vs. Prior Period

• Revenue Increase: Revenue increased 65% to $102.5 million, driven primarily by a $55.8 million increase from Ipsen. This included the derecognition of $53.2 million in deferred revenue following Ipsen's decision not to advance the STRO-003 program. This was partially offset by a decrease in revenue from Astellas and Tasly.
• Expense Reductions: R&D expenses decreased 34% ($85.6 million) and G&A expenses decreased 15% ($7.4 million) due to strategic reprioritization and workforce reductions.
• Restructuring: The company incurred $53.4 million in restructuring costs in 2025, compared to none in 2024. This included $26.1 million for the deprioritization of the luvelta (STRO-002) program, $15.8 million in severance, and $9.8 million in contract terminations.
• Liquidity: Cash and marketable securities decreased significantly from $316.9 million to $141.4 million, reflecting operating cash outflows of $177.2 million.

Guidance, Outlook, and Management Commentary

• Pipeline Focus: Management has deprioritized the late-stage candidate luvelta (STRO-002) and is focusing resources on three wholly-owned preclinical programs: STRO-004 (TF-targeted ADC), STRO-006 (ITGβ6-targeted ADC), and STRO-227 (PTK7-targeted dual-payload ADC).
• Clinical Progress:
  • STRO-004: Phase 1 trial initiated in November 2025. Dose escalation is ongoing; initial data expected mid-2026.
  • STRO-006: IND-enabling activities underway; potential IND filing in 2026.
  • STRO-227: CMC activities initiated; IND filing anticipated late 2026 or early 2027.
• Manufacturing Strategy: The company ceased operations at its San Carlos GMP manufacturing facility in 2025 and has transitioned to an external manufacturing strategy using Contract Manufacturing Organizations (CMOs).
• Liquidity Outlook: Management believes existing cash resources, combined with proceeds from a February 2026 underwritten offering (approx. $110 million gross), will fund operations for at least the next 12 months.
• Risks: Key risks include the failure of product candidates in clinical trials, inability to secure additional funding, dependence on third-party manufacturers, and the impact of the Blackstone royalty monetization agreement on future cash flows.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $141.4 million cash balance plus the February 2026 offering proceeds to fund the accelerated development of STRO-004, STRO-006, and STRO-227 without further dilution.
• STRO-004 Data: Monitor the timing and quality of the initial Phase 1 data expected in mid-2026, specifically regarding safety and tolerability compared to the approved competitor TIVDAK.
• Restructuring Completion: Confirm the final costs associated with the luvelta program wind-down and the exit from the San Carlos facility to ensure no unexpected future liabilities.
• Collaboration Revenue: Assess the sustainability of revenue streams from Astellas and Vaxcyte, noting the recent termination of the Ipsen STRO-003 program.
• Manufacturing Transfer: Validate the successful technology transfer to third-party CMOs to ensure no supply chain disruptions for clinical trials.